Moderna reaches $103 billion as melanoma trial success raises profit questions
Moderna's November 4 rally returned its equity value to a level seen during the COVID vaccine boom. Positive Phase 3 melanoma evidence has changed the clinical case, but Merck's profit share and the cost of making a treatment for each patient leave the cash flow case unresolved.
Moderna closed November 4 at $258.48, up $30.04 or 13.15%, giving it a market capitalization of $103.19 billion ahead of November 6 earnings, according to StockAnalysis. That is roughly the value it carried at the end of 2021, when COVID vaccine sales supported a very different business; at the end of 2025, it was worth approximately $11.52 billion, according to historical market data.
The question is what portion of today's valuation can eventually be supported by profits from its newly validated melanoma program.
Positive melanoma results still need to become a business
On August 19, Moderna and Merck announced that the randomized Phase 3 INTerpath-001 study of intismeran autogene, also called mRNA-4157, plus Keytruda met its recurrence and distant metastasis endpoints in high risk resected melanoma.
The October clinical disclosure reported 1,137 randomized patients.
At two years, recurrence free survival was 82.2% with the combination versus 70.0% with Keytruda alone, an absolute difference of 12.2 percentage points and a recurrence or death hazard ratio of 0.58. Distant metastasis free survival was 88.5% versus 80.2%, an 8.3 percentage point difference, with a hazard ratio of 0.62.
That is substantive randomized efficacy evidence for the studied melanoma setting, although overall survival remains immature.
In ESMO's clinical commentary, Copenhagen University Hospital's Inge Marie Svane said, “The reported HRs are convincing.” She also raised competition from treatment before surgery and the speed of individualized manufacture.
The distinction matters for Moderna's other development programs, including Phase 3 non small cell lung cancer trials.
In August, BioNTech discontinued a separate Phase 2 individualized cancer immunotherapy study in colorectal cancer following a futility recommendation and a numerical overall survival imbalance.
Its drug, tumor and treatment regimen differed, but the setback illustrates why success in one tumor setting cannot automatically validate another.
The November 4 announcements are earlier stage
On the day of the share price jump, Moderna reported four confirmed responses among 11 evaluable patients in an early Phase 1/2 multiple myeloma study of mRNA-2808, a distinct T cell engager approach. Twelve people had been treated, and 41.7% experienced Grade 3 or higher adverse events related to treatment.
The cohort is too small to establish response durability or commercial potential; updated data are scheduled for December 12 to 15.
Separately, WHO advisers recommended including investigational Ebola vaccine mRNA-1469 in a Democratic Republic of Congo Phase 2/3 study, conditional on national approvals. These announcements add potential applications, but neither establishes product sales, and the available chronology cannot apportion the 13.15% rally among them, the already public melanoma data or trading conditions.
How Moderna would share profits with Merck
The profit-sharing terms are in Moderna's SEC filing.
Moderna and Merck generally share worldwide intismeran development costs and any profits or losses equally, subject to exceptions. Merck generally leads clinical trials and Moderna leads process development and manufacturing. This is not a simple entitlement to half of gross cancer drug sales.
To assess the value, start with authorization, eligible patients and reimbursed treatment. Then subtract individualized production and other program expenses before applying Moderna's contractual profit share.
The supplied financial information establishes no commercial treatment price, eligible patient volume or production cost from which to calculate that profit. An approximately six week personalized production cycle discussed in October reporting is an interview estimate, not an audited commercial throughput figure.
Moderna does have other authorized products: the FDA lists mFLUSIVA as approved for adults aged 50 and older, while its June SEC filing records European approval of the flu and COVID combination product mCOMBRIAX. These authorizations broaden its commercial opportunities without establishing sales volumes or margins.
The share price has moved faster than the financial evidence
At roughly 399.24 million shares outstanding, the November 4 close reproduces a $103.19 billion equity valuation. Against $2.23 billion in trailing revenue, that is approximately 46.3 times sales; trailing net loss was $3.15 billion, according to StockAnalysis.
The multiple describes the scale of future performance embedded in the price rather than a valuation of the cancer program. The provider's $138.37 average analyst target, drawn from 23 analysts, was approximately 46.5% below the close, but differing estimate dates and assumptions prevent treating that spread as an immediate fair value calculation.
StockAnalysis also listed enterprise value of $97.57 billion, implying a $5.62 billion net cash adjustment. Its underlying balance sheet, however, predates Moderna's July $950 million settlement payment and completed September 1 sale of $3 billion in zero coupon convertible notes. The chart therefore compares the quoted equity value with a vendor enterprise value that is not a verified November 4 financial position.
Moderna held $6.91 billion of cash, equivalents and investments on June 30, compared with $8.135 billion at the end of 2025. In the first half, it used $1.156 billion of cash in operations and spent $99 million on capital expenditure, a simplified $1.255 billion outflow before investment portfolio transactions.
Its $2.125 billion first half GAAP net loss and the $950 million legal accrual do not translate directly into a continuing cash burn rate, particularly because settlement cash was paid in July. An additional payment of up to $1.3 billion remains conditional on specified legal appeal outcomes, rather than being an established payable.
The interim filing and settlement disclosure define those separate exposures.
The September financing generated approximately $2.957 billion of net note proceeds, of which $328.8 million funded capped calls. The November 4 close exceeded the notes' initial $210.58 conversion price, although conversion conditions and capped call protection prevent treating that as immediate dilution.
A current liquidity and debt reconciliation requires the next quarterly balance sheet.
What the next results and milestones can show
The most likely outcome through February 5, 2027 is continued operating losses while oncology remains in development, assuming no major clinical or regulatory reversal. November 6 earnings and the November 12 Analyst Day can clarify spending, liquidity and manufacturing plans; the December myeloma presentation can test whether its initial response signal strengthens.
By November 5, 2027, a plausible upside would require regulatory progress in melanoma alongside credible manufacturing and reimbursement economics. Negative results in other tumors or persistent production difficulties would weaken the wider platform case.
By November 5, 2029, regulatory outcomes, actual patients treated, time from biopsy to dose and reported collaboration contributions could provide a stronger test of the economics than today's revenue multiple. Those outcomes would still need to be interpreted alongside Moderna's respiratory business and capital structure.
CTOL expects Moderna to report a third quarter GAAP operating loss on November 6 with high qualitative confidence; zero or positive GAAP operating income for the quarter would falsify that call.